Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide.

Trial Profile

Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms TemAvIr
  • Most Recent Events

    • 29 May 2015 Time to health-related quality of life deterioration results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 24 Sep 2012 Lead trial centre changed from Federation Nationale des Centres de Lutte Contre le Cancer to UNICANCER as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top